Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

by Werth, Victoria P , Delev, Nikolay , Liu, Zhaohui , Velasco, Jorge , van Vollenhoven, Ronald , Majdan, Maria , Weiswasser, Michael , Furie, Richard , Petronijevic, Milan , Ye, Ying , Merrill, Joan T , Agafonova, Nataliya , Schafer, Peter H , Dörner, Thomas , Gaudy, Allison , Korish, Shimon , Irazoque-Palazuelos, Fedra

in Adaptor Proteins, Signal Transducing - agonists / Adult / Allergy / Autoimmunity / Clinical Medicine / Clinical Medicine General / Clinical trials / Dermatology / Dermatology General / Dose-Response Relationship, Drug / Double-Blind Method / Female / Humans / Ikaros protein / Ikaros Transcription Factor - metabolism / Immunology / Immunology General / Laboratories / Lupus / Lupus Erythematosus, Systemic - drug therapy / Lupus Erythematosus, Systemic - ethnology / Male / Middle Aged / Morpholines - administration & dosage / Morpholines - pharmacology / Morpholines - therapeutic use / Nephrology / Nephrology General / Neutropenia / Patients / Phthalimides - administration & dosage / Phthalimides - pharmacology / Phthalimides - therapeutic use / Piperidones - administration & dosage / Piperidones - pharmacology / Piperidones - therapeutic use / Placebos / Respiratory tract diseases / Rheumatology / Rheumatology General / Severity of Illness Index / Statistical analysis / Systemic lupus erythematosus / Transcription factors / Ubiquitin-Protein Ligases - metabolism / Urinary tract

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

2022

Confirm

Do you wish to request the book?

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

Werth, Victoria P,

Delev, Nikolay,

Liu, Zhaohui,

Velasco, Jorge,

van Vollenhoven, Ronald,

Majdan, Maria,

Weiswasser, Michael,

Furie, Richard,

Petronijevic, Milan,

Ye, Ying,

Merrill, Joan T,

Agafonova, Nataliya,

Schafer, Peter H,

Dörner, Thomas,

Gaudy, Allison,

Korish, Shimon,

Irazoque-Palazuelos, Fedra

2022

Overview

In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred in 54% of those who received iberdomide (0.45 mg), as compared with 35% in the placebo group, but this between-group difference was not significant at lower doses. Urinary tract and respiratory tract infections and neutropenia occurred.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adaptor Proteins, Signal Transducing - agonists

/ Adult

/ Allergy

/ Autoimmunity

/ Clinical Medicine

/ Clinical Medicine General

/ Clinical trials